Trial ID or NCT#

NCT04500756

Status

recruiting iconRECRUITING

Purpose

In this research, the investigators are looking at the effects of a drug called metformin may have on the growth of abdominal aortic aneurysm (AAA)s. AAA is an abnormal enlargement of the aorta, which is the large artery in the abdomen (stomach area). The enlargement of the aorta carries a risk that it will rupture and cause life-threatening bleeding in the abdomen (belly). In this study the investigators hope to learn how metformin is associated with the enlargement or change in size of the AAA in study participants. Smaller studies have suggested that metformin may reduce the rate at which aortic aneurysms enlarge. This study will test this question: does metformin prevent AAAs from growing larger?

Official Title

LIMItIng AAA With meTformin (LIMIT) Trial

Eligibility Criteria

Ages Eligible for Study: 55 Years to 90 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Ronald L. Dalman MD
Ronald L. Dalman MD
Vascular surgeon
Dr. Walter C. Chidester Professor
Ying Lu

Contact us to find out if this trial is right for you.

CONTACT

Ed Finn, MA
(650) 724-6167